{"title":"Almac详细介绍了扩展计划","authors":"None Rick Mullin","doi":"10.1021/cen-10137-buscon17","DOIUrl":null,"url":null,"abstract":"Almac has published details of a $98 million investment program that will expand its pharmaceutical and diagnostic service units with manufacturing and laboratory assets at its headquarters in Craigavon, Northern Ireland. Plans include a 9,300 m 2 production facility supporting oral dosage drugs and a 3,700 m 2 development center with diagnostic kit manufacturing facilities. Alma, which has set a recruitment goal of 1,000 new staffers in Northern Ireland over 3 years, says this expansion will create more than 550 jobs.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"29 23","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Almac details expansion plans\",\"authors\":\"None Rick Mullin\",\"doi\":\"10.1021/cen-10137-buscon17\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Almac has published details of a $98 million investment program that will expand its pharmaceutical and diagnostic service units with manufacturing and laboratory assets at its headquarters in Craigavon, Northern Ireland. Plans include a 9,300 m 2 production facility supporting oral dosage drugs and a 3,700 m 2 development center with diagnostic kit manufacturing facilities. Alma, which has set a recruitment goal of 1,000 new staffers in Northern Ireland over 3 years, says this expansion will create more than 550 jobs.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"29 23\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10137-buscon17\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10137-buscon17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Almac has published details of a $98 million investment program that will expand its pharmaceutical and diagnostic service units with manufacturing and laboratory assets at its headquarters in Craigavon, Northern Ireland. Plans include a 9,300 m 2 production facility supporting oral dosage drugs and a 3,700 m 2 development center with diagnostic kit manufacturing facilities. Alma, which has set a recruitment goal of 1,000 new staffers in Northern Ireland over 3 years, says this expansion will create more than 550 jobs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
